Sherlock Bio to buy UK firm in quest for CRISPR-based handheld…

Feb 1 (Reuters) — Privately-held Sherlock Biosciences said on Wednesday it has acquired UK-based Sense Biodetection to speed up the launch of handheld diagnostic tests that use the breakthrough CRISPR gene editing technology. Sherlock raised $80 million nearly a year ago for url shortener development of diagnostics based on the CRISPR tool, which is designed…

Read More